Welcome to our dedicated page for Immutep American Depositary Shares news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep American Depositary Shares stock.
Immutep Limited (NASDAQ: IMMP) is a globally active biotechnology company focusing on the development of innovative immunotherapy products for cancer and autoimmune diseases. Listed on both the Australian Stock Exchange and the Nasdaq Global Market in the U.S., Immutep is at the forefront of personalized bio-therapeutic treatment options.
At the core of Immutep's research and development is the LAG-3 immune control mechanism, crucial for the regulation of the T cell immune response. The company's flagship product, IMP321, a T cell immunostimulatory factor (APC activator), has completed Phase II clinical trials for cancer chemo-immunotherapy. This product is designed to enhance the body's immune response to cancer, providing a novel treatment option for patients.
In addition to IMP321, Immutep is advancing several other LAG-3 related products. These include IMP701, a blocking anti-LAG-3 antibody for cancer currently in Phase I clinical trials, and CVac, a personalized immunocellular therapeutic being investigated for the treatment of epithelial cancer. The development of these products is supported through partnerships with large pharmaceutical companies, aiming to accelerate the availability of these innovative treatments.
Immutep's operations are headquartered in Australia, with the majority of its revenue derived from product sales. The company remains committed to maximizing shareholder value through its technological expertise and robust pipeline of products.
For investors, Immutep represents a significant opportunity in the biotechnology sector, with its cutting-edge research and promising clinical advancements poised to make a substantial impact on cancer and autoimmune disease treatment.
Immutep Limited has announced positive progress in its Phase IIb TACTI-003 trial, with the Independent Data Monitoring Committee recommending the continuation of the trial with no modifications. The trial evaluates eftilagimod alpha in combination with KEYTRUDA® for treating head and neck squamous cell carcinoma. Currently, 34% of the 154 patients have been recruited, and the FDA has granted Fast Track designation for this combination therapy, facilitating quicker clinical development and potential approval.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced its clinical development strategy focusing on eftilagimod alpha (efti) for treating non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), and metastatic breast cancer (MBC). Positive interim data from the TACTI-002 trial in NSCLC showed favorable results compared to standard chemotherapy. Additionally, the FDA granted Fast Track designation for efti in 1st line NSCLC. The company holds a strong cash position of $73.9 million, extending its financial runway into early 2024.
Immutep will present initial data from its INSIGHT-003 clinical trial at the upcoming SITC Annual Meeting 2022 in Boston from November 8-12. The trial evaluates the safety and efficacy of eftilagimod alpha combined with chemotherapy and anti-PD-1 therapy in patients with non-small-cell lung cancer (NSCLC) adenocarcinomas. A poster presentation will be held on November 11, with a focus on a cohort of 20 patients. Additionally, Immutep will present a TACTI-003 trial progress poster on November 10. The company aims to advance its innovative cancer treatments.
Immutep Limited (NASDAQ: IMMP) has announced that the US FDA granted Fast Track designation for eftilagimod alpha (efti) in combination with pembrolizumab for treating 1st line non-small cell lung cancer (NSCLC). This follows encouraging Phase II clinical results presented at ASCO 2022. The designation facilitates the expedited development and review process, allowing more frequent communication with the FDA. This is the second Fast Track designation for efti, which highlights its potential as a novel, chemotherapy-free treatment option for NSCLC patients.
Immutep Limited, a clinical-stage biotechnology company, announced participation in two investor conferences: the Cantor Fitzgerald's Oncology Conference on September 28, 2022, and the Ladenburg Thalmann Healthcare Conference on September 29, 2022. CEO Marc Voigt and COO Deanne Miller will discuss trends and challenges in immuno-oncology. A live webcast of the Ladenburg presentation will be available on Immutep's website. The company focuses on developing LAG-3 related immunotherapies for cancer and autoimmune diseases, aiming to provide innovative treatments.
Immutep (ASX: IMM; NASDAQ: IMMP) announced a €1,804,341 (~A$2,693,046) cash payment from the French Government under the Crédit d’Impôt Recherche (CIR) scheme. This R&D tax incentive supports eligible expenditure incurred during the 2021 calendar year for research in Europe. The funds will be allocated for the ongoing global clinical development of eftilagimod alpha and the preclinical development of IMP761. Immutep also qualifies for Australian R&D tax rebates, enhancing its financial position for future projects.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has provided an update on its eftilagimod alpha clinical trials, highlighting promising Phase II results in non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), and metastatic breast cancer (MBC). The company is prioritizing 1L NSCLC for late-stage trials, with significant data expected in Q4 2022. Efti has shown strong clinical benefits especially in patients with low PD-L1 expression, suggesting a broad therapeutic potential. With approximately $80 million in cash, Immutep is funded for its expansion into early 2024.
Immutep Limited (NASDAQ: IMMP) appointed Professor Frédéric Triebel as Executive Director, enhancing its leadership team. Triebel, known for his groundbreaking work on the LAG-3 gene at Institut Gustave Roussy, has been pivotal in developing LAG-3-related therapies. His appointment aligns with Immutep’s commercialization strategy, focusing on their lead candidate, eftilagimod alpha, which shows promising clinical results and safety. With ongoing advancements and growing industry recognition, Immutep is well-positioned in the immunotherapy market.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces the expansion of its efti clinical development pipeline with a new Phase II trial targeting soft tissue sarcoma. The study, funded by a €1.5M (approx. A$2.2M) grant from the Polish government, will assess efti in combination with pembrolizumab and radiotherapy in up to 40 patients. The first patient is expected to begin dosing by H1 2023, with initial data anticipated in Q4 2024. The trial is a collaboration with the Maria Skłodowska-Curie National Research Institute of Oncology, enhancing efti's potential in cancer treatment.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced the granting of a new patent by the Japanese Patent Office, enhancing its intellectual property portfolio for eftilagimod alpha (efti), a LAG-3 fusion protein. This patent protects therapeutic combinations of efti with anti-PD-(L)1 antibodies, alongside specific claims for various approved combinations. Following similar patents granted globally, this strengthens Immutep's position in the biotech sector. The patent will expire on January 8, 2036.
CEO Marc Voigt emphasized the significance of this development in conjunction with promising data from recent clinical trials.
FAQ
What is the current stock price of Immutep American Depositary Shares (IMMP)?
What is the market cap of Immutep American Depositary Shares (IMMP)?
What is Immutep Limited?
What products does Immutep specialize in?
What is the LAG-3 immune control mechanism?
What is IMP321?
What are the other key products in Immutep's pipeline?
With which markets is Immutep affiliated?
Where is Immutep headquartered?
What are Immutep's key partnerships?
How does Immutep generate revenue?
Why should investors consider Immutep?
